Related Experiment Video
Updated: Jan 13, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
SCAMP3 and EPS8 Cooperatively Regulate EGFR Signaling to Promote Enzalutamide Resistance and Metastatic Potential in
Wei-Lun Huang1,2,3, Pei-Fang Hsieh1,4, Sih-Han Chen1,2,3
1Division of Urology, Department of Surgery, E-Da Hospital, Kaohsiung, Taiwan, R.O.C.
Background/Aim:
Prostate cancer is the second most common malignancy among men worldwide, with progression to castration-resistant prostate cancer (CRPC) posing significant therapeutic challenges. Enzalutamide, a second-generation androgen receptor antagonist, initially demonstrates efficacy in treating metastatic CRPC; however, resistance inevitably develops. Dysregulation of the epidermal growth factor receptor (EGFR) signaling pathway has been implicated in therapy resistance and metastatic progression. Secretory carrier membrane protein 3 (SCAMP3) and epidermal growth factor receptor substrate 8 (EPS8) are known regulators of EGFR trafficking and signaling. This study aimed to investigate their cooperative roles in enzalutamide-resistant prostate cancer cells.
Materials And Methods:
LNCap prostate cancer cells and their enzalutamide-resistant derivatives (LNCap-Enz) were treated with 100 ng/ml epidermal growth factor (EGF). Protein expression and interactions were analyzed by Western blotting and co-immunoprecipitation. SCAMP3 and EPS8 were knocked down using shRNA technology, while complementary overexpression studies were conducted using pcDNA-SCAMP3 and pcDNA-EPS8 vectors. Effects on EGF receptor (EGFR) expression and downstream signaling molecules (STAT3, AKT, ERK) were evaluated in both loss-of-function and gain-of-function models.
Results:
EGF stimulation enhanced the expression of EGFR, SCAMP3, and EPS8 in both LNCap and LNCap-Enz cells while promoting formation of a protein complex involving these proteins and the androgen receptor (AR-V7). Knockdown of SCAMP3 or EPS8 reduced EGFR expression and attenuated STAT3, AKT, and ERK activation. Conversely, overexpression of SCAMP3 or EPS8 increased EGFR levels and enhanced downstream signaling activation. These bidirectional effects highlight the functional interdependence between SCAMP3 and EPS8 in regulating EGFR stability and signaling.
Conclusion:
SCAMP3 and EPS8 cooperatively maintain EGFR stability and signaling in prostate cancer cells, playing a critical role in enzalutamide resistance and metastatic progression. Targeting the SCAMP3-EPS8-EGFR axis offers promising therapeutic opportunities for advanced prostate cancer.
Insights
Secretory carrier membrane protein 3 (SCAMP3) and epidermal growth factor receptor substrate 8 (EPS8) work together to stabilize epidermal growth factor receptor (EGFR) signaling. This pathway is crucial for enzalutamide-resistant prostate cancer progression and offers a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Prostate cancer progression to castration-resistant prostate cancer (CRPC) presents treatment challenges.
- Enzalutamide resistance is a significant issue in metastatic CRPC.
- Epidermal growth factor receptor (EGFR) pathway dysregulation contributes to therapy resistance.
Purpose of the Study:
- Investigate the cooperative roles of SCAMP3 and EPS8 in enzalutamide-resistant prostate cancer cells.
- Determine the impact of SCAMP3 and EPS8 on EGFR signaling.
- Explore their potential as therapeutic targets.
Main Methods:
- Utilized LNCap and LNCap-Enz prostate cancer cell lines.
- Analyzed protein expression and interactions via Western blotting and co-immunoprecipitation.
- Performed gene knockdown (shRNA) and overexpression (pcDNA vectors) of SCAMP3 and EPS8.
- Assessed effects on EGFR and downstream signaling (STAT3, AKT, ERK).
Main Results:
- EGF stimulation increased EGFR, SCAMP3, and EPS8 expression and promoted complex formation with AR-V7.
- SCAMP3 or EPS8 knockdown reduced EGFR expression and attenuated downstream signaling.
- Overexpression of SCAMP3 or EPS8 enhanced EGFR levels and signaling.
- Demonstrated functional interdependence between SCAMP3 and EPS8 in regulating EGFR.
Conclusions:
- SCAMP3 and EPS8 cooperatively maintain EGFR stability and signaling in prostate cancer.
- This SCAMP3-EPS8-EGFR axis is critical for enzalutamide resistance and metastasis.
- Targeting this axis presents a promising therapeutic strategy for advanced prostate cancer.
More Related Videos
Related Concept Videos
02:38Mitogens and the Cell Cycle
03:03mTOR Signaling and Cancer Progression
The mTOR pathway or the...